CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Tumescent solution with dilute lidocaine and epinephrine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01602692
NCT01602692Phase 4Completed
CompareCT.gov

A Comparison of Tumescence in Breast Reduction Surgery

University of Wisconsin, Madison·interventional·Posted May 21, 2012·Updated Oct 5, 2020

In Brief

A Phase 4 clinical trial evaluating Tumescent solution with dilute lidocaine and epinephrine and Tumescent Solution with dilute epinephrine for Pain, Postoperative and Postoperative Nausea and Vomiting. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The investigators' main hypothesis is that in breast reduction surgery, the use of tumescent solution containing both dilute lidocaine and epinephrine will lead to better control of postoperative pain, nausea, vomiting, shorter time through postoperative phases of care, quicker discharge from the hospital and lower numbers of hospital readmissions than the use of tumescent solution containing only dilute epinephrine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative, Postoperative Nausea and Vomiting
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 21, 2012
Enrollment StartAug 1, 2012
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.1 years ago

Interventions

Tumescent solution with dilute lidocaine and epinephrinedrug

Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)

Tumescent Solution with dilute epinephrinedrug

Tumescent Solution containing dilute epinephrine (1:1,000,000) only